McCurdyDKFredericMElkintonR. Renal tubular acidosis due to amphotericin B. N Engl J Med1968; 278: 124–30.
3.
SaidRMarinPAnicamaHQuintanillaALevinML. Effect of mannitol on acute amphotericin B nephrotoxicity. Res Exp Med1980; 177: 185–90.
4.
GerkensJFBranchRA. The influence of sodium status and furosemide on canine acute amphotericin B nephrotoxicity. J Pharmacol Exp Ther1980; 172: 85–9.
5.
BhathenaDBBullockWFNuttallCELukeRG. The effects of amphotericin B therapy on the intrarenal vasculature and renal tubules in man. Clin Nephrol1978; 9: 103–10.
6.
HeidemannHTGerkensJFSpickardWAJacksonEKBranchRA. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med1983; 75: 476–81.
7.
BullockWELukeRGNuttallCEBhathenaDB. Can mannitol reduce amphotericin B nephrotoxicity?Antimicrob Agents Chemother1976; 10: 555–63.
8.
MorissCRAlexanderEABrunsFLLevinskyNG. Restriction and maintenance of glomerular filtration by mannitol during hypoperfusion of kidney. J Clin Invest1972; 51: 1555–63.
9.
GerkensJFHeidemannHTJacksonEKBranchRA. Effect of aminophylline on amphotericin B nephrotoxicity in the dog. J Pharmacol Exp Ther1983; 274: 609–13.
10.
FeelyJHeidemannHGerkensJRobertsLJBranchRA. Sodium depletion enhances nephrotoxicity of amphotericin B. Lancet1981; 1: 1422–3.
11.
ReinerNEThompsonWL. Dopamine and saralasin antagonism of renal vasoconstriction and oliguria caused by amphotericin B in dogs. J Infect Dis1979; 140: 564–74.
12.
GraybillJRCravenPC. Antifungal agents used in systemic mycoses—activity and therapeutic use. Drugs1983; 25: 41–62.
13.
EllisWGSobelRANielsenSL. Leukoencephalopathy in patients treated with amphotericin B methyl ester. J Infect Dis1982; 146: 125–37.
14.
MadduxMSBarriereSL. A review of complications of amphotericin B therapy: Recommendations for prevention and management. Drug Intell Clin Pharm1980; 14: 177–81.
15.
MillerRPBatesJH. Amphotericin B toxicity: A follow up report of 53 patients. Ann Intern Med1969; 71: 1089–95.
16.
Drugs for treatment of systemic fungal infections.Med Lett Drug Ther1982; 24: 36–8.
17.
HermansPEKeysTF. Antifungal agents used for deepseated mycotic infections. Mayo Clin Proc1983; 58: 223–32.
18.
JessupEB. Chymopapain for the treatment of herniated lumbar disc disease. Hosp Pharm1983; 18: 371–4.
RodenbaughFH. Pre-treatment for contrast media reactions (letter). Radiology Images (San Jose Hospital Radiology Department) 1983; 1(July) 2.
23.
Webb-JohnsonDCAndrewsJL. Bronchodilator therapy. N Engl J Med1977; 297: 476–82.
24.
RichelsonE. Tricyclic antidepressants and histamine H1 receptors. Mayo Clin Proc1979; 54: 669–74.
25.
ChangRSLTranVTSnyderSH. Heterogeneity of histamine H1 receptors: Species variations in (3H) mepyramine binding of brain membranes. J Neurochem1979; 32: 1653–63.
26.
KanofPDGreengardP. Brain histaminic receptors as targets for antidepressant drugs. Nature1978; 272: 329–33.
27.
ShenWWMahadevanJHofstatterLSataLS. Doxepin as a potent H1 and H2 antihistamine for epigastric distress. Am J Psychiatry1983; 140: 957–8.
28.
SullivanTJ. Pharmacologic modulation of the whealing response to histamine in human skin: Identification of doxepin as a potent in vivo inhibitor. J Allergy Clin Immunol1982; 69: 260–7.
29.
KehrlJHFauciA. The clinical use of glucocorticoids. Ann Allergy1983; 50: 2–8.
30.
FAUCI A, moderator. NIH Conference. Glucocorticoid therapy: mechanism of action and clinical considerations. Ann Intern Med1976; 84: 304–15.
31.
Chemonucleolysis—anaphylaxis: recognition and treatment.Northbrook, IL: Smith Laboratories, 1983.
32.
HutchcroftBJMooreEOrangeRP. H1 and H2 antihistamines in allergic reactions (abstract). J Allergy Clin Immunol1978; 61: 192.
33.
HarveyRPSchocketAL. The effect of H1 and H2 blockade on cutaneous histamine response in man. J Allergy Clin Immunol1980; 65: 136–9.
34.
PhilbinDMMossJAkinsCWThe use of H1 and H2 histamine antagonists with morphine anesthesia: A double-blind study. Anesthesiology1981; 55: 292–6.
35.
In vitro test for chymopapain hypersensitivity.Drug Info News (UCLA Drug Information Center) 1983; 5 (26) 56.
36.
ChurchMKCollierHOJamesGW. The inhibition by dexamethasone and disodium cromoglycate of anaphylactic bronchoconstriction. Br J Pharmacol1972; 46: 56–65.
37.
BartlettJGMoonNChangTWRole of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology1978; 75: 778–82.
38.
TedescoFMarkhamRGurwithMOral vancomycin for antibiotic-associated pseudomembranous colitis (letter). Lancet 178;2: 226.
39.
CherryRDPortnoyDJabbariMMetronidazole: An alternative therapy for antibiotic-associated colitis. Gastroenterology1982; 82: 849–51.
40.
ChangTWGorbachSLBartlettJGSaginurR. Bacitracin treatment of antibiotic-associated colitis and diarrhea caused by Clostridium difficile toxin. Gastroenterology1980; 78: 1584–6.
41.
KeuschGTPresentDH. Summary of a workshop on clindamycin colitis. J Infect Dis1976; 133: 578.
42.
GeorgeWLRolfeRDFinegoldSM. Treatment and prevention of antimicrobial agent-induced colitis and diarrhea. Gastroenterology1980; 79: 366–72.
43.
DinhTHKernbaumSFrottierJ. Treatment of antibiotic-associated colitis by metronidazole (letter). Lancet1978; 1: 338.
44.
EglintonGSMayesGRPottsDW. Pseudomembranous colitis unresponsive to oral vancomycin therapy. South Med J1982; 75: 1279–80.
PortnoyDSonejiAMurrayDRichardsGK. Pseudomembranous colitis: Multiple relapses after treatment with metronidazole. Can Med Assoc J1981; 124: 1603–4.
47.
TeasleyDGGerdingDNOlsonMMProspective randomized trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhea and colitis. Lancet1983; 2: 1043–6.
48.
MoggGAGBurdonDWKeighleyM. Oral metronidazole in Clostridium difficile colitis (letter). Br Med J1979; 2: 335.